Home› Situations› ABBV — Gap to peers
Situation · 2026-06-12

ABBV — Gap to peers

Premium Valuation Faces Regulatory and Transition Risks

Updated 2026-06-10 · Ref: Drug Manufacturers - General
Key metrics — 2026-06-10
Peer score
37
Quality pct
29
Valuation pct
15
52w drawdown
-5.8%
21d vs sector
+5.0%
Peer group
Drug Manufacturers - General
Situation summary

AbbVie’s strong profitability (ROIC 10.17%, margin 34.1%) supports its premium, yet regulatory and product transition risks keep the valuation from being fully protected. Revenue growth and new drug launches remain solid. Current stress centers on regulatory reforms and reliance on key products. A more defensible premium would require broader revenue diversification and easing regulatory uncertainty.

Published by AssetNext · 2026-04-20

All companies with this signal today

View full list: Gap to peers →

Related pages for ABBV
Full peer analysis for AbbVie Inc. →Similar companies to ABBVABBV peersAll ABBV comparisonsS&P 500 context
Signal history — last 30 days
Date Signal Peer score Drawdown 21d vs sector
2026-06-10 Gap to peers 37 -5.8% +5.0%

See ABBV's full peer analysis

Break down ABBV's structural position across all peer dimensions with the interactive app.

Open ABBV in AssetNext →